Page 18 - Pharma Sector

Big Pharma's bet on China biotech a rare trade bright spot amid tensions

Chinese biomedical research is on the cusp of a breakthrough just as the industry starts to face serious headwinds

AstraZeneca Pharma gets nod for sale, distribution of cancer drug Lynparza

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults

Orchid Pharma to collaborate with hospital body CAHO to counter AMR

The collaboration aims to tackle AMR in India by focusing on tier 2 and tier 3 cities, bridging the gap between awareness and action, and ensuring sustainable AMR interventions

Why has Aurobindo Pharma stock gained 3% in trade today, November 25?

The collaboration and licencing agreement is set to span three to five years and focuses on the joint development of specific products within the respiratory therapeutic area, Aurobindo Pharma said

Pharma industry expo to be held in Greater Noida from November 26-28

The 17th edition of the CPHI and PMEC expo showcasing the pharmaceutical industry's modernisation, innovation and sustainability will be held from November 26 to 28 in Greater Noida. The expo will this year offer a pivotal marketplace for over 2,000 exhibitors to engage with anticipated participation from countries, including the US, UAE, South Korea, Japan, Egypt, Vietnam, the Philippines, Malaysia, Italy, Sri Lanka, Bangladesh, Nepal, Iran, and the United Kingdom. The expo will showcase over 10,000 products, offering a unique space for collaboration and innovation in the pharma industry, said a release from the organiser Informa Markets in India. The noteworthy exhibitors include Dr Reddy's Laboratories Ltd, Biocon Ltd, Glenmark Lifesciences Ltd, Morepen Laboratories Ltd, Hetero Labs Limited, Lupin Ltd, Signet Excipients Pvt. Ltd, MSN Laboratories Pvt. Ltd, Sekhmet Pharmaventures Pvt. Ltd, Tirupati Lifesciences Pvt. Ltd, Merck Life Science Pvt. Ltd. and many others, the statement

Exports, domestic demand to drive pharma revenue growth: SME Tracker

SMEs manufacture and market formulations based on less complex molecules, given their higher exposure to generic products

Glenmark Pharma Q2 results: PAT rises to Rs 354 cr on chronic drugs demand

The drugmaker reported a consolidated profit of Rs 354 crore (nearly $42 million) for the quarter ended Sept. 30, compared with a loss of Rs 81.95 crore a year ago

India needs to expand local vaccine manufacturing, research: GTRI report

India needs to expand its local vaccine manufacturing and research to give better control over safety of these pharma products, think tank GTRI said on Monday. The Global Trade Research Initiative (GTRI) also suggested the government to launch an investigation to track all adverse health events post-vaccination as this could help make future vaccine rollouts more transparent, safe and effective. "Expanding local vaccine manufacturing and research can give India better control over vaccine safety, ensuring vaccines meet local needs and are tailored to the population's health characteristics," it said in a report. It added that these suggestions assume importance in the backdrop of the October 2024 release of "The Pfizer Papers: Crimes Against Humanity" which has ignited global debate over vaccine safety, ethics and transparency. "As the world prepares for future pandemics, the insights from The Pfizer Papers provide a foundation for building safer, more effective and more trustworth

Indian pharmaceutical market registers over 6% growth in October 2024

The value growth comes at a time when the IPM has registered a negative volume growth of 1.8 per cent

Lupin Q2FY25 results: Net profit jumps 74% to Rs 853 cr on strong demand

Consolidated net profit of the company, which makes biosimilars and active pharmaceutical ingredients, rose to Rs 853 crore (about $101 million) for the quarter ended Sept. 30

Novo Nordisk expects high demand for obesity drugs in India: Country head

The company is still 'evaluating' the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo's India Managing Director Vikrant Shrotriya said

High-growth segments, Tier II, III cities to drive long-term gains for ABB

Some large orders were postponed and government capex has seen delays

'Higher tariffs on Indian pharma, auto likely under Trump's America First'

With Donald Trump all set to become US president, Indian exporters may face high customs duties for goods like automobiles, textiles and pharmaceuticals if the new US administration decides to pursue the America First' agenda, opined trade experts. Experts also said that Trump could also tighten H-1B visa rules, impacting costs and growth for Indian IT firms. Over 80 per cent of India's IT export earnings come from the US, making it vulnerable to changes in visa policies. The US is India's largest trading partner, accounting for over USD 190 billion of annual trade. Global Trade Research Initiative (GTRI) Founder Ajay Srivastava said that Trump may extend tariffs beyond China to include India and other countries. Trump had earlier called India a "large tariff abuser" and in October 2020 labelled India as the 'tariff king'. These remarks suggest that Trump's second term could bring tougher trade negotiations. he said. "His America First agenda would likely push for protective mea

Piramal Pharma soars 13% on heavy volumes; up 42% in 2 weeks post Q2 show

Till 12:35 pm; a combined 32.3 million shares representing 2.43 per cent of total equity of PPL changed hands on the NSE and BSE.

Dr Reddy's Q2 results: PAT falls 9.5% to Rs 1,342 cr on weak US demand

The company reported a 9.5 per cent fall in its consolidated net profit

Gland Pharma soars 13% on better than expected Q2 performance

Despite increased EBITDA loss at Cenexi, the overall consolidated EBITDA margin was better-than-expected at 21.1%, led by better segmental mix and controlled operational cost for the quarter.

Gland Pharma Q2FY25 results: Net profit falls 15.7% to Rs 164 crore

The company reported consolidated net profit of Rs 164 crore ($19.5 million) for the quarter ended Sept. 30, a 15.7 per cent decrease from the year-ago period

Torrent Investments sells 2.9% stake in Torrent Pharma for Rs 3,086 cr

Torrent Investments, a promoter entity of Torrent Pharmaceuticals, on Wednesday trimmed a 2.9 per cent stake in the company for Rs 3,086 crore through open market transactions. According to the bulk deal data available with the BSE, Torrent Investments Pvt Ltd sold a total of 99.44 lakh shares or 2.94 per cent stake in Torrent Pharmaceuticals. The shares were sold in the price range of Rs 3,103.07-3,104.40 apiece, taking the combined transaction value to Rs 3,086.37 crore. After the stake sale, the combined holding of promoters of Torrent Pharmaceuticals has come down to 68.31 per cent from 71.25 per cent. Details of the buyers of Torrent Pharmaceuticals' shares could not be ascertained on the BSE. Last week, Torrent Pharmaceuticals reported its consolidated profit after tax rose 17 per cent to Rs 453 crore in the September quarter, led by robust sales in the domestic market. The drug firm had reported a profit after tax (PAT) of Rs 386 crore in the July-September period of the l

GlaxoSmithKline Pharma Q2 results: Net profit rises 16% to Rs 252 cr

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs 252 crore in the September quarter, aided by robust sales across segments. The drug maker posted a net profit of Rs 217 crore for the July-September quarter of last fiscal. Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. The company said its board declared a special interim dividend of Rs 12 per equity share of face value of Rs 10 each. "As we mark our centenary year in India, we are happy to announce a special interim dividend to our shareholders. Our performance reflects our commitment to sustainable growth and innovation," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The drugmaker said its key brands held their market share and continued to stay in line with the respective category performance. Augmentin ..

NPPA asks pharma manufacturers to cut price of 3 anti-cancer drugs

The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of customs duty exemption and GST reduction to the consumers. In line with the government's commitment to ensure the availability of drugs at affordable prices, the National Pharmaceutical Pricing Authority (NPPA) has issued an office memorandum directing the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab. This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty, the Ministry of Chemicals and Fertilisers said in a statement. The Department of Revenue, Ministry of Finance, issued a notification dated July 23, this year reducing the customs duty to nil on the three drugs. "Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes and duties should be passed on to the consumers,"